Investigating long noncoding RNAs in breast cancer among African-American women
Long noncoding RNA regulations in breast cancer among African-American women
This study is looking at how certain molecules in our genes, called long noncoding RNAs, might affect breast cancer in African-American women, who often face tougher challenges with the disease, to help find out why this happens and improve their treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10874630 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of long noncoding RNAs (lncRNAs) in breast cancer specifically among African-American women, who are known to experience higher rates of aggressive tumors and poorer outcomes. The study employs advanced genome-wide sequencing techniques to analyze lncRNA expression in both normal and tumor breast tissues, aiming to identify unique expression patterns that may contribute to the disparities in breast cancer prognosis. By comparing these patterns between African-American and European-American women, the research seeks to uncover biological mechanisms that drive aggressive tumor behavior in African-American women.
Who could benefit from this research
Good fit: Ideal candidates for participation are African-American women diagnosed with breast cancer, particularly those with aggressive tumor types.
Not a fit: Patients who do not have breast cancer or are not African-American women may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding of breast cancer biology in African-American women, potentially informing more effective treatment strategies and interventions.
How similar studies have performed: While research on lncRNAs in cancer is ongoing, this specific focus on African-American women and the use of high-throughput sequencing represents a novel approach that has not been extensively tested.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Gong, Zhihong — Roswell Park Cancer Institute Corp
- Study coordinator: Gong, Zhihong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.